AC Immune SA has reported encouraging interim results from its phase 2 VacSYn clinical trial of ACI-7104.056, an anti-alpha-synuclein (a-syn) active immunotherapy for early Parkinson’s disease (PD).

GlobalData analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Experts made the discovery after analysing hours of YouTube footage of celebrities with the disease - and it paves the way ...

AC Immune (NASDAQ:ACIU) stock shot up 20% Thursday after the company reported positive interim data from a Phase 2 study of ...

For the Cook family, supporting Cure Parkinson's is a personal cause as Joyce's son, Will, was close friends with the late Tom Isaacs, one of the founders of the charity. Will is also the former CEO ...

Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...